Safety, Efficacy, And Health-Related Quality Of Life (Hrqol) Of The Investigational Single Agent Orteronel (Ortl) In Nonmetastatic Castration-Resistant Prostate Cancer (Nmcrpc)

5076 Background: Ortl is a selective, non-steroidal, oral 17,20-lyase inhibitor. Due to its lower inhibition of 17α-hydroxylase vs 17,20-lyase, ortl may allow steroid-free dosing. Ortl 300 mg BID was studied in nmCRPC patients (pts). Methods: Pts with nmCRPC, PSA ≥2 ng/mL (PSA ≥8 ng/mL if doubling time u003e8 mo), and testosterone (T) 12 mo. 6 had dose reduction, 12 discontinued due to adverse events (AEs), including 2 for possible adren...